Welcome to our dedicated page for INFI news (Ticker: INFI), a resource for investors and traders seeking the latest updates and insights on INFI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INFI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INFI's position in the market.
Summary not available.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a conference call scheduled for November 9, 2020, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020, and provide company updates. Infinity is advancing its first-in-class immuno-oncology product candidate, eganelisib, which selectively inhibits PI3K-gamma and is being evaluated in various clinical studies. Investors can access the call via toll-free and international dial-in numbers or through a live webcast available on Infinity's website.
Infinity Pharmaceuticals (NASDAQ: INFI) announced that the FDA has granted Fast Track designation for eganelisib in combination with chemotherapy and a checkpoint inhibitor for treating inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). The company is currently enrolling patients in the Phase 2 MARIO-3 study, in collaboration with Roche/Genentech. This designation facilitates expedited drug development for serious conditions. Earlier in the year, Infinity received a similar designation for eganelisib in treating advanced urothelial cancer.